Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $2.49 million. The enterprise value is -$1.08 million.
| Market Cap | 2.49M |
| Enterprise Value | -1.08M |
Important Dates
The next estimated earnings date is Friday, February 28, 2025, before market open.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 2.46 million shares outstanding. The number of shares has increased by 518.34% in one year.
| Current Share Class | 2.46M |
| Shares Outstanding | 2.46M |
| Shares Change (YoY) | +518.34% |
| Shares Change (QoQ) | +50.07% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 5.29% |
| Float | 2.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.87
| Current Ratio | 14.87 |
| Quick Ratio | 13.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -109.17% and return on invested capital (ROIC) is -63.02%.
| Return on Equity (ROE) | -109.17% |
| Return on Assets (ROA) | -52.87% |
| Return on Invested Capital (ROIC) | -63.02% |
| Return on Capital Employed (ROCE) | -100.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.68M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.10% in the last 52 weeks. The beta is 0.82, so Bone Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -74.10% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 44.75 |
| Average Volume (20 Days) | 291,023 |
Short Selling Information
The latest short interest is 155,013, so 6.29% of the outstanding shares have been sold short.
| Short Interest | 155,013 |
| Short Previous Month | 75,614 |
| Short % of Shares Out | 6.29% |
| Short % of Float | 6.43% |
| Short Ratio (days to cover) | 0.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.82M |
| Pretax Income | -5.12M |
| Net Income | -7.35M |
| EBITDA | n/a |
| EBIT | -3.82M |
| Earnings Per Share (EPS) | -$7.27 |
Balance Sheet
| Cash & Cash Equivalents | 3.57M |
| Total Debt | n/a |
| Net Cash | 3.57M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 3.79M |
| Book Value Per Share | 1.81 |
| Working Capital | 3.79M |
Cash Flow
| Operating Cash Flow | -4.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.79M |
| FCF Per Share | -$1.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bone Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -518.34% |
| Shareholder Yield | -518.34% |
| Earnings Yield | -295.52% |
| FCF Yield | -192.49% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 20, 2023. It was a reverse split with a ratio of 0.125:1.
| Last Split Date | Dec 20, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.125:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |